Moreover, our data revealed that LAPTM4B expression was markedly associated with the clinical‐pathological features, including tumor size (P = 0.004*) and clinical stage (P = 0.035*), of patients with osteosarcoma. Here, LAPTM4B is linked to osteosarcoma.